For the first time in Ukraine there was done farmacoeconomical analysis of direct costs for multiple sclerosis (MS) using the methodology “cost of illness”. The cost of pathogenetic treatment courses and direct cost for one patient for one year were calculated. The annual costs for one case of relapsing-remitting MS course was 10 417.34 grn, secondary progressive course — 11 681.34 grn and primary-progressive course — 13 164.74 grn. Despite of high cost of preventing treatment there was shown an economical benefits of its use due to quality adjusted life years (QALY) saving, prevention of neurological deficits accumulation and shortened of direct costs.